Innovative translational research in leukemia is critically dependent on the availability of funding for pilot projects. The Leukemia SPORE Developmental Research Program (DRP) will be a source of seed funding with the following goals: 1) encourage and explore innovative translational research ideas which focus on leukemia research;and 2) encourage successful researchers working in other fields to focus their expertise toward the development of innovative translational projects in leukemia research. Both laboratory and clinical research projects are eligible for funding, provided that they are translational in nature. The purpose of the SPORE Developmental Research Program is to develop translational research projects that should result in clinically-testable hypotheses aimed at improving prognosis for patients with leukemia. Support of $100,000 from the SPORE and $100,000 from matching institutional support as described in the letter of Institutional Commitment will provide a total of $200,000 per year available through the Developmental Research Program for approximately 4 to 5 projects (approximately $50,000 per project). Funding will be awarded for 1 year;with satisfactory review from the respective advisory committees and progress on the individual projects'specific aims, the funding could be carried over for an additional year. The specific objectives of the Developmental Research Program are to: 1. Publicize the availability of funds for pilot translational leukemia research studies. Identify through this mechanism innovative projects with significant potential for improving leukemia therapy and prognosis. 2. Encourage collaborations of projects with scientists within the SPORE and outside the SPORE. 3. Enhance the communication between the SPORE leaders and outside investigators to encourage the development of innovative translational strategies in leukemia. 4. Ensure program flexibility so that developmental projects that show promise can be: 1) funded for a second year;2) encouraged to apply for peer-reviewed funding (i.e. R01);or 3) expanded to become full SPORE projects. Lay Description: Innovative translational research in leukemia is critically dependent on the availability of funding for pilot projects. The Leukemia SPORE Developmental Research Program will be a source of seed funding with the following goals: 1) encourage and explore innovative translational research ideas which focus on leukemia research;and 2) encourage successful researchers working in other fields to focus their expertise toward the development of innovative translational projects in leukemia research

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-10
Application #
8378217
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2013-08-31
Budget Start
2012-06-20
Budget End
2013-04-30
Support Year
10
Fiscal Year
2012
Total Cost
$74,474
Indirect Cost
$52,004
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Kayser, Sabine; Levis, Mark J (2018) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol 180:484-500
Xia, Fang; Ning, Jing; Huang, Xuelin (2018) Empirical Comparison of the Breslow Estimator and the Kalbfleisch Prentice Estimator for Survival Functions. J Biom Biostat 9:
Trujillo-Ocampo, Abel; Cho, Hyun-Woo; Herrmann, Amanda C et al. (2018) Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease. Cytotherapy 20:1089-1101
Cortes, Jorge E; Tallman, Martin S; Schiller, Gary J et al. (2018) Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML. Blood 132:598-607
Ohanian, Maro; Rozovski, Uri; Kanagal-Shamanna, Rashmi et al. (2018) MYC protein expression is an important prognostic factor in acute myeloid leukemia. Leuk Lymphoma :1-12
Boddu, P; Jorgensen, J; Kantarjian, H et al. (2018) Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia 32:241-244
Yan, Fangrong; Zhu, Huihong; Liu, Junlin et al. (2018) Design and inference for 3-stage bioequivalence testing with serial sampling data. Pharm Stat 17:458-476
Kelly, Andrew D; Madzo, Jozef; Madireddi, Priyanka et al. (2018) Demethylator phenotypes in acute myeloid leukemia. Leukemia 32:2178-2188
Levis, Mark J; Perl, Alexander E; Altman, Jessica K et al. (2018) A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. Blood Adv 2:825-831

Showing the most recent 10 out of 487 publications